Get More Information on Drug Screening Market - Request Sample Report
The Drug Screening Market was valued at USD 7.6 billion in 2023 and is expected to reach USD 29.7 billion by 2032 and grow at a CAGR of 16.3% over the forecast period 2024-2032.
There has been an increasing trend of substance abuse across the globe, resulting in increased demand for drug-testing solutions to promote the growth of the market for drug screening. It is being strictly regulated by governments all over the world to make alcohol and drug testing compulsory in certain workplaces and public places for safety reasons. Furthermore, more government initiatives undertaken to monitor and combat this menace are an added support to the growth of the market. For instance, the National Institute on Drug Abuse report shows that in 2021, over 106,000 people in the U.S. died from drug overdoses, which sets an intense need for reliable drug testing. More than 50% of workplace accidents and 40% of employee theft can be traced back to substance abuse, according to the U.S. Department of Justice, which fuels further the demand for drug testing solutions.
Several governmental initiatives are reinforcing the market's growth. For example, the U.S. government passed the Consolidated Appropriations Act of 2023, under which funding is allocated to SAMHSA to support programs related to substance use disorders. In Canada, the SUAP also finances several drug prevention and treatment projects. Additionally, in December of 2021, the UK launched its 10-year plan on driving down drugs-related crimes and supporting recovery from addiction, providing yet another example of a collective push globally toward subduing substance abuse.
Advances in drug testing technologies point-of-care and rapid testing solutions are driving growth in the market. New products such as Singapore's saliva test kit for roadside drug detection illustrate product development within the market. However, the regulatory environment is challenging, especially in high-market-potential areas, which slows the approval of new technologies.
Leading players like F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., and Bio-Rad Laboratories, Inc. are leading the market through product innovations and strategic mergers. For instance, in 2023, BRITISH CANNABIS acquired PhytoVista Laboratories, enhancing their drug testing capabilities. The competition would be of moderate levels because of the presence of advanced breathalyzers and sweat patch tests. However, the level of concentration is high due to the end-users in the research and diagnostics industries.
Table: SWOT Analysis of the Drug Screening Market
| Strengths | Weaknesses |
|---|---|
| High demand for drug screening tests | High costs associated with advanced technologies |
| Established market players | Regulatory challenges |
| Continuous technological advancements | Limited awareness in emerging markets |
| Opportunities | Threats |
|---|---|
| Expansion into emerging markets | Intense competition |
| Increased focus on personalized medicine | Rapid technological changes |
| Collaborations and partnerships | Changes in regulatory frameworks |
Drivers
Rising Drug and Alcohol Consumption Fuels Demand for Drug Screening Solutions
Some of the most important factors that help develop the drug screening market are the increasing use of drugs and alcohol. According to the World Drug Report 2023, it is estimated that in 2021, approximately 1 in every 17 people aged 15–64 had used a drug during the past year. In that same year, the number of users increased from 240 million in 2011 to 296 million, and for that, this constituted a 23% increase. This rise has been traced in part to population growth; cannabis is the second most used drug, with 219 million users, or 4.3% of the adult world population.
Drug use is not the only concern: alcohol-related problems also include violent and other crimes. One instance of that in the United States is alcohol-impaired driving crashes, which accounted for 13,384 deaths in 2021, 14% more than a year earlier, according to data from the U.S. Department of Transportation's National Highway Traffic Safety Administration. The rising incidence of illegal drug and alcohol use is increasing the demand for suitable drug screening solutions, especially in road safety testing and workplace testing. As a result, the demand for drug screening products and services will increase geometrically, thereby propelling the overall market growth.
Restraints
Strict Alcohol Bans in Islamic Countries
Cultural and Religious Prohibitions
By Product
The consumables segment dominated the market in 2023, holding a share of 36.2% spurred by the significant role consumables like kits, reagents, columns, calibrators, blue dye tablets, specimen, and temperature test strips, and controls serve for drug testing. All these consumables are important for boosting confirmation testing. In June 2023, the Office of Addiction Services and Supports launched a statewide ordering system for xylazine test strips, reportedly ordering nearly 100,000. The system will offer free test strips to the public and clinicians, providing a core component of harm reduction to combat the risks posed by xylazine and its expanding illicit trade. This development is expected to induce further growth in the market over time.
Rapid testing devices are expected to record the fastest growth over the review period due to the fast rise in substance use, including opioids. WHO estimates that 296 million people globally used drugs at least once in 2021, and about 60 million of those comprised opioid users. The increased intake of opioids and other drugs will lead to increased demand for rapid testing devices. Besides, strategic programs like new product developments, partnerships, and mergers & acquisitions by state and non-state agencies promote programs to limit drug abuse, thereby driving market growth. For instance, recently this October 2023, Kerala Police initiated the SoToxa Mobile Test, which is a portable rapid drug testing kit, based on human saliva samples, where the result can be delivered within five minutes. This system can detect drug use up to two days prior, further advancing rapid testing technology.
By Sample Type
The urine sample segment was the market leader in 2023, with a greater share of 40.1%. This is mainly due to the rising collection of urine for testing purposes. UDM plays a crucial role in maintaining adherence to prescribed regimens and avoiding misuse or abuse of substances. UDM is highly beneficial in screening patients with opioid therapy to maintain compliance and detect misuse. Additionally, urine testing is one of the very few methods that are acceptable both by the Department of Health as well as the Department of Transportation. These samples would be for use in both point-of-care as well as laboratory diagnostics.
The oral fluid segment will be the fastest-growing during the forecast period. Oral fluid samples detect drug concentrations that are essentially correlated with plasma levels, which makes them good for the identification of recent use, cases of impairment, and many other conditions. However, oral fluid samples need proper equipment for collection to maintain the integrity of the samples. Quantification, for instance, is sometimes tricky with oral fluid samples, as some devices used for collection absorb the fluid collected, resulting in less accurate identification results for drugs. Despite these challenges, however, developments in product formulation and the introduction of special collection devices, such as Oral-Eze, improved the efficiency and reliability of oral fluid sample collection.
By Drug
The cannabis/marijuana segment led the market throughout the year 2023 with the highest share of 24.6%. This is mainly because cannabis is the most abused illegal drug, which also drives demand for testing kits and equipment. The higher use of cannabis in major markets increases the demand for testing supplies and instruments.
The cannabis/marijuana segment is also expected to grow the fastest within the forecast period. In the U.S., marijuana is classified as a hallucinogen under the Controlled Substances Act, hence it is not legal at the federal level, though it has been legalized and decriminalized for recreational use in many states. Some other countries that have legalized its use recently include Canada, parts of the United States, and Uruguay. The fact that cannabis is the most commonly abused illicit substance worldwide means that the market for testing solutions is also expected to continue along that trend in the following years. Increased demand for legal cannabis due, among others, to medical use, remains one of the fundamental drivers that have boosted the market in previous years. Many countries have recently legalized medical marijuana to treat a myriad of other conditions. There have been many studies that indicate how effective medical marijuana can be for symptom relief in substance use disorders as well as other medical issues.
By End Use
The drug testing laboratories segment accounted for the largest share of 36.0% in 2023. Such dominance can be attributed to the wide reach and comprehensive services offered by testing laboratories. These often have testing capabilities for a wide range of substances, which is generally not the case in rapid tests. Moreover, rigorous testing procedures ensure better accuracy in the results obtained from laboratory tests, which becomes very important while initiating appropriate treatment by drug use or overdose.
The workplace segment is likely to be the largest growing segment during the forecast period. Public and private organizations have rigid policies for the non-existence of drugs in the workplace, thereby fueling growth. In this regard, most employers in the drug abuse testing market conduct pre-employment tests as well as periodic tests for currently employed employees. Urine tests are the most widely used form of workforce drug testing, and some of the major users are government agencies and employers. Also tested for in these tests include amphetamines, marijuana, methamphetamines, cocaine, Phenylcyclohexyl Piperidine (PCP), and opiates. Increasing demand for keeping the premises drug-free at companies is the primary motivating factor behind the growth in this sector of workplace drug testing.
North American drug screening market also dominated with a high 39.5% share in 2023 with the presence of key market players like Bio-Rad Laboratories and stringent government regulations towards substance abuse, further accented by the move such as San Francisco's need to enroll anybody seeking county funds in treatment. Alcohol consumption is likely to rise in the United States to align with growing markets and reported high usage levels of cannabis and prescription stimulants are also likely to fuel the U.S. market.
The market for drug testing is growing in Europe, especially in the UK and France, which is more driven by greater safety awareness in the workplace and investment from governments to control the abuse of drugs. Funding has been provided by the UK Office for Life Sciences that advances the testing technologies, whereas France is witnessing greater demands for testing based on increasing illicit consumption of drugs.
The region with the fastest growth is likely to be Asia Pacific, which will be influenced by a more dynamic government action plan to prevent drug use and advances in testing technology. Countries like China and Japan are seriously expanding their ability to conduct drug tests: not only have they been deploying new rapid test kits but also collaborative efforts to improve their services as rates of youth substance abuse continue to increase.
Need any customization research on Drug Screening Market- Enquiry Now
Omega Laboratories, Inc.
Psychemedics Corporation
Labcorp
Abbott
Thermo Fisher Scientific Inc.
Alfa Scientific Designs, Inc.
OraSure Technologies Inc.
ACM Global Laboratories
CareHealth America Corp
Sciteck, Inc.
F. Hoffmann-La Roche Ltd
MPD Inc.
Shimadzu Corporation
Lifeloc Technologies, Inc.
Drägerwerk AG & Co. KGaA
Clinical Reference Laboratory, Inc.
American Bio Medica Corporation
Intoximeters, Inc.
AccuSourceHR, Inc.
Cordant Health Solutions
Intoxalock
Millennium Health and Others.
In February 2024, Swedish sample collection company Capitainer announced a successful fundraising round securing an amount of USD 7.7 million using Series A financing. This capital raising will be used to increase and improve production capacity and strengthen its sales platform in its self-sampling blood collection products in the EU and the US and drive significant collaborations.
In Feb 2024, Veriteque announced a new distribution agreement with OraSure Technologies, which is a leading developer of in vitro diagnostic products. According to this deal, Veriteque will employ OraSure's rapid POC tests for various infectious diseases, such as HIV, HCV, and syphilis, within some specific territories. This partnership aims to provide greater access to these critical, life-saving tests among healthcare providers and patients within those certain areas.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | USD 7.6 Billion |
| Market Size by 2032 | USD 29.7 Billion |
| CAGR | CAGR of 16.3% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product (Consumables, Instruments, Rapid Testing Devices, Services) • By Sample Type (Urine Samples, Oral Fluid Samples, Hair Samples, Other Samples) • By Drug (Alcohol, Cannabis/Marijuana, Cocaine, Opioids, Amphetamine & Methamphetamine, LSD, Others) • By End Use (Drug Testing Laboratories, Workplaces, Hospitals, Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia-Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia-Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Premier Biotech, Inc., Omega Laboratories, Inc., Psychemedics Corporation, Labcorp, Quest Diagnostics, Abbott, Thermo Fisher Scientific Inc., Alfa Scientific Designs, Inc., and Others |
| Key Drivers | • Rising Drug and Alcohol Consumption Fuels Demand for Drug Screening Solutions |
| RESTRAINTS | • Strict Alcohol Bans in Islamic Countries • Cultural and Religious Prohibitions |
Ans: The estimated compound annual growth rate is 16.3% during the forecast period for the Drug Screening market.
Ans: The projected market value of the Drug Screening market is estimated at USD 7.6 billion in 2023 and is expected to reach USD 29.7 billion by 2032.
Ans: Rising drug and alcohol consumption fuels demand for drug screening solutions.
Ans: Strict alcohol bans in Islamic countries are one of the restraints on the Drug Screening market growth.
Ans: North America is the dominant region with a 39.5% share in the Drug Screening market.
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Adoption Trends of Drug Screening Methods (Urine, Blood, Hair, Saliva), by Region (2023)
5.2 Volume of Drug Screening Tests, by Region (2020-2032)
5.3 Healthcare and Occupational Spending on Drug Screening, by Region, (2023)
5.4 Regulatory and Compliance Trends for Drug Screening, by Region (2023)
5.5 Trends in Technology and Innovation in Drug Screening Devices and Kits (2023)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Drug Screening Market Segmentation, by Product
7.1 Chapter Overview
7.2 Consumables
7.2.1 Consumables Market Trends Analysis (2020-2032)
7.2.2 Consumables Market Size Estimates and Forecasts to 2032 (USD Million)
7.3 Instruments
7.3.1 Instruments Market Trends Analysis (2020-2032)
7.3.2 Instruments Market Size Estimates and Forecasts to 2032 (USD Million)
7.4 Rapid Testing Devices
7.4.1 Rapid Testing Devices Market Trends Analysis (2020-2032)
7.4.2 Rapid Testing Devices Market Size Estimates and Forecasts to 2032 (USD Million)
7.5 Services
7.5.1 Services Market Trends Analysis (2020-2032)
7.5.2 Services Market Size Estimates and Forecasts to 2032 (USD Million)
8. Drug Screening Market Segmentation, By Sample Type
8.1 Chapter Overview
8.2 Urine Samples
8.2.1 Urine Samples Market Trends Analysis (2020-2032)
8.2.2 Urine Samples Market Size Estimates and Forecasts to 2032 (USD Million)
8.3 Oral Fluid Samples
8.3.1 Oral Fluid Samples Market Trends Analysis (2020-2032)
8.3.2 Oral Fluid Samples Market Size Estimates And Forecasts To 2032 (USD Million)
8.4 Hair Samples
8.4.1 Hair Samples Market Trends Analysis (2020-2032)
8.4.2 Hair Samples Market Size Estimates And Forecasts To 2032 (USD Million)
8.5 Other Samples
8.5.1 Other Samples Market Trends Analysis (2020-2032)
8.5.2 Other Samples Market Size Estimates And Forecasts To 2032 (USD Million)
9. Drug Screening Market Segmentation, by Drug
9.1 Chapter Overview
9.2 Alcohol
9.2.1 Alcohol Market Trends Analysis (2020-2032)
9.2.2 Alcohol Market Size Estimates and Forecasts to 2032 (USD Million)
9.3 Cannabis/Marijuana
9.3.1 Cannabis/Marijuana Market Trends Analysis (2020-2032)
9.3.2 Cannabis/Marijuana Market Size Estimates and Forecasts to 2032 (USD Million)
9.4 Cocaine
9.4.1 Cocaine Market Trends Analysis (2020-2032)
9.4.2 Cocaine Market Size Estimates and Forecasts to 2032 (USD Million)
9.5 Opioids
9.5.1 Opioids Market Trends Analysis (2020-2032)
9.5.2 Opioids Market Size Estimates and Forecasts to 2032 (USD Million)
9.6 Amphetamine & Methamphetamine
9.6.1 Amphetamine & Methamphetamine Market Trends Analysis (2020-2032)
9.6.2 Amphetamine & Methamphetamine Market Size Estimates and Forecasts to 2032 (USD Million)
9.7 LSD
9.7.1 LSD Market Trends Analysis (2020-2032)
9.7.2 LSD Market Size Estimates and Forecasts to 2032 (USD Million)
9.8 Others
9.8.1 Others Market Trends Analysis (2020-2032)
9.8.2 Others Market Size Estimates and Forecasts to 2032 (USD Million)
10. Drug Screening Market Segmentation, By End Use
10.1 Chapter Overview
10.2 Drug Testing Laboratories
10.2.1 Drug Testing Laboratories Market Trends Analysis (2020-2032)
10.2.2 Drug Testing Laboratories Market Size Estimates and Forecasts to 2032 (USD Million)
10.3 Workplaces
10.3.1 Workplaces Market Trends Analysis (2020-2032)
10.3.2 Workplaces Market Size Estimates and Forecasts to 2032 (USD Million)
10.4 Hospitals
10.4.1 Hospitals Market Trends Analysis (2020-2032)
10.4.2 Hospitals Market Size Estimates and Forecasts to 2032 (USD Million)
10.5 Others
10.5.1 Others Market Trends Analysis (2020-2032)
10.5.2 Others Market Size Estimates and Forecasts to 2032 (USD Million)
11. Regional Analysis
11.1 Chapter Overview
11.2 North America
11.2.1 Trends Analysis
11.2.2 North America Drug Screening Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
11.2.3 North America Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.2.4 North America Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.2.5 North America Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.2.6 North America Drug Screening Market Estimates and Forecasts, By End Use (2020-2032) (USD Million)
11.2.7 USA
11.2.7.1 USA Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.2.7.2 USA Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.2.7.3 USA Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.2.7.4 USA Drug Screening Market Estimates and Forecasts, By End Use (2020-2032) (USD Million)
11.2.8 Canada
11.2.8.1 Canada Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.2.8.2 Canada Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.2.8.3 Canada Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.2.8.4 Canada Drug Screening Market Estimates and Forecasts, By End Use (2020-2032) (USD Million)
11.2.9 Mexico
11.2.9.1 Mexico Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.2.9.2 Mexico Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.2.9.3 Mexico Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.2.9.4 Mexico Drug Screening Market Estimates and Forecasts, By End Use (2020-2032) (USD Million
11.3 Europe
11.3.1 Eastern Europe
11.3.1.1 Trends Analysis
11.3.1.2 Eastern Europe Drug Screening Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
11.3.1.3 Eastern Europe Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.3.1.4 Eastern Europe Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.3.1.5 Eastern Europe Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.3.1.6 Eastern Europe Drug Screening Market Estimates and Forecasts, By End Use (2020-2032) (USD Million)
11.3.1.7 Poland
11.3.1.7.1 Poland Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.3.1.7.2 Poland Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.3.1.7.3 Poland Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.3.1.7.4 Poland Drug Screening Market Estimates and Forecasts, By End Use (2020-2032) (USD Million)
11.3.1.8 Romania
11.3.1.8.1 Romania Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.3.1.8.2 Romania Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.3.1.8.3 Romania Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.3.1.8.4 Romania Drug Screening Market Estimates and Forecasts, By End Use (2020-2032) (USD Million)
11.3.1.9 Hungary
11.3.1.9.1 Hungary Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.3.1.9.2 Hungary Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.3.1.9.3 Hungary Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.3.1.9.4 Hungary Drug Screening Market Estimates and Forecasts, By End Use (2020-2032) (USD Million)
11.3.1.10 Turkey
11.3.1.10.1 Turkey Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.3.1.10.2 Turkey Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.3.1.10.3 Turkey Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.3.1.10.4 Turkey Drug Screening Market Estimates and Forecasts, By End Use (2020-2032) (USD Million)
11.3.1.11 Rest of Eastern Europe
11.3.1.11.1 Rest of Eastern Europe Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.3.1.11.2 Rest of Eastern Europe Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.3.1.11.3 Rest of Eastern Europe Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.3.1.11.4 Rest of Eastern Europe Drug Screening Market Estimates and Forecasts, By End Use(2020-2032) (USD Million)
11.3.2 Western Europe
11.3.2.1 Trends Analysis
11.3.2.2 Western Europe Drug Screening Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
11.3.2.3 Western Europe Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.3.2.4 Western Europe Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.3.2.5 Western Europe Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.3.2.6 Western Europe Drug Screening Market Estimates and Forecasts, By End Use(2020-2032) (USD Million)
11.3.2.7 Germany
11.3.2.7.1 Germany Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.3.2.7.2 Germany Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.3.2.7.3 Germany Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.3.2.7.4 Germany Drug Screening Market Estimates and Forecasts, By End Use(2020-2032) (USD Million)
11.3.2.8 France
11.3.2.8.1 France Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.3.2.8.2 France Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.3.2.8.3 France Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.3.2.8.4 France Drug Screening Market Estimates and Forecasts, By End Use(2020-2032) (USD Million)
11.3.2.9 UK
11.3.2.9.1 UK Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.3.2.9.2 UK Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.3.2.9.3 UK Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.3.2.9.4 UK Drug Screening Market Estimates and Forecasts, By End Use(2020-2032) (USD Million)
11.3.2.10 Italy
11.3.2.10.1 Italy Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.3.2.10.2 Italy Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.3.2.10.3 Italy Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.3.2.10.4 Italy Drug Screening Market Estimates and Forecasts, By End Use(2020-2032) (USD Million)
11.3.2.11 Spain
11.3.2.11.1 Spain Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.3.2.11.2 Spain Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.3.2.11.3 Spain Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.3.2.11.4 Spain Drug Screening Market Estimates and Forecasts, By End Use(2020-2032) (USD Million)
11.3.2.12 Netherlands
11.3.2.12.1 Netherlands Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.3.2.12.2 Netherlands Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.3.2.12.3 Netherlands Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.3.2.12.4 Netherlands Drug Screening Market Estimates and Forecasts, By End Use(2020-2032) (USD Million)
11.3.2.13 Switzerland
11.3.2.13.1 Switzerland Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.3.2.13.2 Switzerland Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.3.2.13.3 Switzerland Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.3.2.13.4 Switzerland Drug Screening Market Estimates and Forecasts, By End Use(2020-2032) (USD Million)
11.3.2.14 Austria
11.3.2.14.1 Austria Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.3.2.14.2 Austria Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.3.2.14.3 Austria Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.3.2.14.4 Austria Drug Screening Market Estimates and Forecasts, By End Use(2020-2032) (USD Million)
11.3.2.15 Rest of Western Europe
11.3.2.15.1 Rest of Western Europe Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.3.2.15.2 Rest of Western Europe Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.3.2.15.3 Rest of Western Europe Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.3.2.15.4 Rest of Western Europe Drug Screening Market Estimates and Forecasts, By End Use(2020-2032) (USD Million)
11.4 Asia Pacific
11.4.1 Trends Analysis
11.4.2 Asia Pacific Drug Screening Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
11.4.3 Asia Pacific Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.4.4 Asia Pacific Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.4.5 Asia Pacific Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.4.6 Asia Pacific Drug Screening Market Estimates and Forecasts, By End Use(2020-2032) (USD Million)
11.4.7 China
11.4.7.1 China Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.4.7.2 China Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.4.7.3 China Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.4.7.4 China Drug Screening Market Estimates and Forecasts, By End Use(2020-2032) (USD Million)
11.4.8 India
11.4.8.1 India Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.4.8.2 India Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.4.8.3 India Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.4.8.4 India Drug Screening Market Estimates and Forecasts, By End Use(2020-2032) (USD Million)
11.4.9 Japan
11.4.9.1 Japan Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.4.9.2 Japan Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.4.9.3 Japan Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.4.9.4 Japan Drug Screening Market Estimates and Forecasts, By End Use(2020-2032) (USD Million)
11.4.10 South Korea
11.4.10.1 South Korea Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.4.10.2 South Korea Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.4.10.3 South Korea Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.4.10.4 South Korea Drug Screening Market Estimates and Forecasts, By End Use(2020-2032) (USD Million)
11.4.11 Vietnam
11.4.11.1 Vietnam Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.4.11.2 Vietnam Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.4.11.3 Vietnam Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.4.11.4 Vietnam Drug Screening Market Estimates and Forecasts, By End Use(2020-2032) (USD Million)
11.4.12 Singapore
11.4.12.1 Singapore Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.4.12.2 Singapore Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.4.12.3 Singapore Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.4.12.4 Singapore Drug Screening Market Estimates and Forecasts, By End Use(2020-2032) (USD Million)
11.4.13 Australia
11.4.13.1 Australia Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.4.13.2 Australia Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.4.13.3 Australia Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.4.13.4 Australia Drug Screening Market Estimates and Forecasts, By End Use(2020-2032) (USD Million)
11.4.14 Rest of Asia Pacific
11.4.14.1 Rest of Asia Pacific Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.4.14.2 Rest of Asia Pacific Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.4.14.3 Rest of Asia Pacific Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.4.14.4 Rest of Asia Pacific Drug Screening Market Estimates and Forecasts, By End Use(2020-2032) (USD Million)
11.5 Middle East and Africa
11.5.1 Middle East
11.5.1.1 Trends Analysis
11.5.1.2 Middle East Drug Screening Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
11.5.1.3 Middle East Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.5.1.4 Middle East Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.5.1.5 Middle East Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.5.1.6 Middle East Drug Screening Market Estimates and Forecasts, By End Use(2020-2032) (USD Million)
11.5.1.7 UAE
11.5.1.7.1 UAE Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.5.1.7.2 UAE Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.5.1.7.3 UAE Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.5.1.7.4 UAE Drug Screening Market Estimates and Forecasts, By End Use(2020-2032) (USD Million)
11.5.1.8 Egypt
11.5.1.8.1 Egypt Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.5.1.8.2 Egypt Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.5.1.8.3 Egypt Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.5.1.8.4 Egypt Drug Screening Market Estimates and Forecasts, By End Use(2020-2032) (USD Million)
11.5.1.9 Saudi Arabia
11.5.1.9.1 Saudi Arabia Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.5.1.9.2 Saudi Arabia Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.5.1.9.3 Saudi Arabia Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.5.1.9.4 Saudi Arabia Drug Screening Market Estimates and Forecasts, By End Use(2020-2032) (USD Million)
11.5.1.10 Qatar
11.5.1.10.1 Qatar Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.5.1.10.2 Qatar Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.5.1.10.3 Qatar Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.5.1.10.4 Qatar Drug Screening Market Estimates and Forecasts, By End Use(2020-2032) (USD Million)
11.5.1.11 Rest of Middle East
11.5.1.11.1 Rest of Middle East Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.5.1.11.2 Rest of Middle East Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.5.1.11.3 Rest of Middle East Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.5.1.11.4 Rest of Middle East Drug Screening Market Estimates and Forecasts, By End Use (2020-2032) (USD Million)
11.5.2 Africa
11.5.2.1 Trends Analysis
11.5.2.2 Africa Drug Screening Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
11.5.2.3 Africa Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.5.2.4 Africa Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.5.2.5 Africa Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.5.2.6 Africa Drug Screening Market Estimates and Forecasts, By End Use(2020-2032) (USD Million)
11.5.2.7 South Africa
11.5.2.7.1 South Africa Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.5.2.7.2 South Africa Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.5.2.7.3 South Africa Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.5.2.7.4 South Africa Drug Screening Market Estimates and Forecasts, By End Use(2020-2032) (USD Million)
11.5.2.8 Nigeria
11.5.2.8.1 Nigeria Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.5.2.8.2 Nigeria Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.5.2.8.3 Nigeria Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.5.2.8.4 Nigeria Drug Screening Market Estimates and Forecasts, By End Use(2020-2032) (USD Million)
11.5.2.9 Rest of Africa
11.5.2.9.1 Rest of Africa Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.5.2.9.2 Rest of Africa Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.5.2.9.3 Rest of Africa Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.5.2.9.4 Rest of Africa Drug Screening Market Estimates and Forecasts, By End Use(2020-2032) (USD Million)
11.6 Latin America
11.6.1 Trends Analysis
11.6.2 Latin America Drug Screening Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
11.6.3 Latin America Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.6.4 Latin America Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.6.5 Latin America Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.6.6 Latin America Drug Screening Market Estimates and Forecasts, By End Use(2020-2032) (USD Million)
11.6.7 Brazil
11.6.7.1 Brazil Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.6.7.2 Brazil Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.6.7.3 Brazil Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.6.7.4 Brazil Drug Screening Market Estimates and Forecasts, By End Use(2020-2032) (USD Million)
11.6.8 Argentina
11.6.8.1 Argentina Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.6.8.2 Argentina Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.6.8.3 Argentina Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.6.8.4 Argentina Drug Screening Market Estimates and Forecasts, By End Use(2020-2032) (USD Million)
11.6.9 Colombia
11.6.9.1 Colombia Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.6.9.2 Colombia Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.6.9.3 Colombia Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.6.9.4 Colombia Drug Screening Market Estimates and Forecasts, By End Use(2020-2032) (USD Million)
11.6.10 Rest of Latin America
11.6.10.1 Rest of Latin America Drug Screening Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
11.6.10.2 Rest of Latin America Drug Screening Market Estimates and Forecasts, By Sample Type (2020-2032) (USD Million)
11.6.10.3 Rest of Latin America Drug Screening Market Estimates and Forecasts, by Drug (2020-2032) (USD Million)
11.6.10.4 Rest of Latin America Drug Screening Market Estimates and Forecasts, By End Use (2020-2032) (USD Million)
12. Company Profiles
12.1 Premier Biotech, Inc.
12.1.1 Company Overview
12.1.2 Financial
12.1.3 Products/ Services Offered
12.1.4 SWOT Analysis
12.2 Omega Laboratories, Inc.
12.2.1 Company Overview
12.2.2 Financial
12.2.3 Products/ Services Offered
12.2.4 SWOT Analysis
12.3 Psychemedics Corporation
12.3.1 Company Overview
12.3.2 Financial
12.3.3 Products/ Services Offered
12.3.4 SWOT Analysis
12.4 Quest Diagnostics
12.4.1 Company Overview
12.4.2 Financial
12.4.3 Products/ Services Offered
12.4.4 SWOT Analysis
12.5 Thermo Fisher Scientific Inc.
12.5.1 Company Overview
12.5.2 Financial
12.5.3 Products/ Services Offered
12.5.4 SWOT Analysis
12.6 Alfa Scientific Designs, Inc.
12.6.1 Company Overview
12.6.2 Financial
12.6.3 Products/ Services Offered
12.6.4 SWOT Analysis
12.7 ACM Global Laboratories
12.7.1 Company Overview
12.7.2 Financial
12.7.3 Products/ Services Offered
12.7.4 SWOT Analysis
12.8 CareHealth America Corp
12.8.1 Company Overview
12.8.2 Financial
12.8.3 Products/ Services Offered
12.8.4 SWOT Analysis
12.9 Sciteck, Inc.
12.9.1 Company Overview
12.9.2 Financial
12.9.3 Products/ Services Offered
12.9.4 SWOT Analysis
12.10 F. Hoffmann-La Roche Ltd
12.10.1 Company Overview
12.10.2 Financial
12.10.3 Products/ Services Offered
12.10.4 SWOT Analysis
13. Use Cases and Best Practices
14. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segmentation
By Product
By Sample Type
By Drug
By End Use
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
Europe
Asia Pacific
Middle East & Africa
Middle East
Africa
Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
The Medical Isotope Market was valued at USD 5.66 billion in 2023 and is expected to reach USD 12.15 billion by 2032, growing at a CAGR of 8.87% over the forecast period 2024-2032.
The Retinal Surgery Market was valued at USD 2.46 billion in 2023 and is expected to reach USD 4.16 billion by 2032 and grow at a CAGR of 6.05% by 2024-2032
The Digital Radiology Market was estimated at USD 3.8 billion in 2023 and is projected to reach USD 5.04 billion by 2031, developing at a CAGR of 3.6% from 2024 to 2031.
PET-CT Scanner Device Market was valued at USD 2.30 billion in 2023 and is anticipated to touch USD 3.98 billion by 2032 with a growing CAGR of 6.30%.
The Microcarriers Market size was estimated at USD 1.52 billion in 2023 and is expected to reach USD 4.11 billion by 2032 at a CAGR of 11.7% during the forecast period of 2024-2032.
The Virology Specimen Collection Market Size was valued at USD 6.11 billion in 2023 and is expected to reach USD 9.22 billion by 2031 and grow at a CAGR of 5.29% over the forecast period 2024-2031.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
